Rivaroxaban Misfires in Antiphospholipid Syndrome Rivaroxaban Misfires in Antiphospholipid Syndrome
Rivaroxaban not only failed to show noninferiority to warfarin, but trended toward higher thrombosis risk in patients with APS.Medscape Medical News
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Source Type: news
More News: Antiphospholipid Syndrome | Cardiology | Coumadin | Heart | Hughes Syndrome | Thrombosis | Warfarin